Refine by
Cancer Related Gene Mutation Detection Suppliers & Manufacturers
50 companies found
based inNottingham, UNITED KINGDOM
Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based ...
EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells. EarlyCDT Lung is the world’s most thoroughly validated blood test for the ...
based inMilan, ITALY
Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer. Tethis’ technology points to standardization of the blood sample preparation to provide ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
ISET, Isolation by SizE of Tumor Cells, is based on the antibody-independent whole blood filtration approach for CTCs and micro-emboli isolation. The solution relies on the larger size of all types of CTCs as compared to the majority ...
based inNatick, MASSACHUSETTS (USA)
DYSIS Medical is a medical device company that designs, develops, manufactures and markets imaging systems focusing on the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. DYSIS Medical has developed a proprietary technology ...
based inGeorgetown, TEXAS (USA)
Ezra is focused on early cancer detection through the use of full-body MRI scans. Given that early detection significantly increases survival rates, Ezra's annual Full Body Scans aim to identify cancer signs early, potentially preventing late-stage ...
Ezra offers advanced MRI-based full-body scans aimed at early cancer detection. The service employs 3 Tesla (3T) MRI technology, known for its higher-resolution imaging and superior signal-to-noise ratio, alongside 1.5 Tesla (1.5T) MRI for broader ...
based inHuntsville, ALABAMA (USA)
Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease ...
based in, CALIFORNIA (USA)
At Delee we’re fundamentally changing not only the way cancer is detected but also how it could be treated. By developing a device capable of capturing Circulating Tumor Cells (CTCs) in a faster and more effective way than the current technologies ...
based inOrlando, FLORIDA (USA)
Imaging Diagnostic Systems, Inc. (IDSI) is a medical device company headquartered in Florida, specializing in the research, development, and marketing of innovative cancer detection systems. Their flagship product, the CTLM system (Computed ...
Computed Tomography Laser Mammography (CTLM) is an innovative imaging method focused on visualizing blood distribution within the breast, helpful for identifying breast abnormalities. This technology offers potential advantages in detecting ...
based inGuildford, UNITED KINGDOM
Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that ...
CancertrackTM is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. CancertrackTM can be used to monitor the disease /recurrence or changes in the tumor ...
based inCleveland, OHIO (USA)
Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. The Company’s Solvent Interaction Analysis ...
IsoPSA Proceed to biopsy only when needed. IsoPSA is now included in NCCN® Prostate Cancer Early Detection Guidelines. IsoPSA can help reduce unnecessary prostate biopsies by up to 55%. Up to 75% of results from prostate biopsies performed in ...
based inSugar Land, TEXAS (USA)
TransLite LLC is a small high tech company comprising dedicated people who design, manufacture and sell medical devices that can help reduce the pain and trauma to patients during venous access and treatment of varicose veins. Over 70,000 medical ...
based inSan Antonio, TEXAS (USA)
Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company formed to commercialize a new modality in cancer screening and diagnosis called opto-acoustic imaging. A strong, experienced management team and nationally ...
based inMiserey, FRANCE
Innovative Solutions for Cancer Diagnostics. OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...
based inNew York, NEW YORK (USA)
Acuamark Diagnostics develops technology which allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team of scientific and business ...
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per year over the next two decades, causing deaths to rise to 13M per ...
based inKiel, GERMANY
QuantView GmbH specializes in advancing MRI technology through revolutionary signal amplification methods, utilizing a quantum mechanical technique for enhanced image resolution. By focusing on hyperpolarized MRI technology, QuantView significantly ...
based inSeville, SPAIN
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are developing Signal-X™, a multi-cancer platform able to detect various types of high-burden ...
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. ...
based inGuangzhou, CHINA
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy ...
Cancer is a complicated disease caused by genetic variation. The genetic variation may deprive cells of the normal control function, leading to immortalization and cancer. And targeted drugs work well in cancer therapy, which can kill cancer cells ...
based inLa Jolla, CALIFORNIA (USA)
Avelas is a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection. Avelas is focused on the development and commercialization of pegloprastide (also referred to as “AVB-620”), a novel ...
Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is designed to deliver a fluorescent marker specifically to cancer cells to enable surgeons to identify cancerous tissue in real-time and thus, avoid repeat ...